30
PD-L1
Expression Level
Objective Response Rate
Nivolumab
Investigator’s Choice
n/N
%
n/N
%
≥ 1%
15/88
17.0
1/61
1.6
≥ 5%
12/54
22.2
1/43
2.3
≥ 10%
12/43
27.9
1/34
2.9
< 1%
9/73
12.3
4/38
10.5
< 5%
12/107
11.2
4/56
7.1
< 10%
12/118
10.2
4/65
6.2
Objective Response Rate by PD-L1 Expression
Nivolumab in R/M SCCHN After Platinum Therapy
